Balyasny Asset Management
CPRX

Balyasny Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Balyasny Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-51,815
Closed -$803K – 2793
2024
Q2 		$803K Buy
+51,815
New +$807K ﹤0.01% 1872
2024
Q1 		– Sell
-57,467
Closed -$966K – 2694
2023
Q4 		$966K Buy
+57,467
New +$786K ﹤0.01% 1704
2022
Q4 		– Sell
-34,516
Closed -$443K – 2844
2022
Q3 		$443K Buy
+34,516
New +$409K ﹤0.01% 2072
2018
Q2 		– Sell
-40,710
Closed -$97K – 1827
2018
Q1 		$97K Buy
+40,710
New +$135K ﹤0.01% 1833
2017
Q4 		– Sell
-14,800
Closed -$37K – 2091
2017
Q3 		$37K Buy
+14,800
New +$40.6K ﹤0.01% 1824

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Balyasny Asset Management's CPRX Position: Q3 2024 in Review

Balyasny Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2024, closing a stake of 51,815 shares — an estimated $803K sold.

Balyasny Asset Management first reported a position in CPRX in Q3 2017 and held it in 5 quarters. The position peaked at $966K in Q4 2023. 316 funds tracked by Wall St. Rank hold CPRX as of Q3 2024.

  • Balyasny Asset Management reported no remaining Catalyst Pharmaceutical position as of Q3 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 51,815 Catalyst Pharmaceutical shares in Q3 2024, an estimated $803K.
  • Balyasny Asset Management first reported a position in Catalyst Pharmaceutical in Q3 2017 and held it in 5 quarters.
  • Balyasny Asset Management's Catalyst Pharmaceutical position peaked at $966K in Q4 2023.
  • 316 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2024.

Based on Balyasny Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.